Physician profile
Steven D Murray
NPI 1619055886
$2,276.70
in general payments reported to CMS, 2019-2025
22 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $476 · 2021: $353 · 2022: $135 · 2023: $223 · 2024: $164 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $950.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $318.13 | 2019-2021 | |
| Novo Nordisk INC | $216.87 | 2019-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $128.60 | 2019-2020 | |
| Abbvie INC. | $110.11 | 2021-2023 | |
| Glaxosmithkline, LLC. | $107.60 | 2019-2020 | |
| Amgen INC. | $55.21 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.87 | 2019-2020 | |
| Allergan, INC. | $48.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.31 | 2020-2023 | Ofev |
| Sanofi-Aventis U.S. LLC | $34.91 | 2019-2020 | |
| Amarin Pharma, INC. | $27.36 | 2019 | |
| Lilly USA, LLC | $26.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $26.44 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $19.27 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $18.97 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.11 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.08 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.88 | 2019 | |
| Dexcom, INC. | $14.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2020 | |
| Astellas Pharma US INC | $13.68 | 2023 | Myrbetriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.